Etcembly
ApprovedFrom Code to Cure: Etcembly combines cutting-edge artificial intelligence and bioengineering to accelerate therapeutic innovation and design next-generation immunotherapies. Learn how we’re shaping the future of precision medicine.
Founded
2018
Focus
AI / Machine LearningBiologics
About
From Code to Cure: Etcembly combines cutting-edge artificial intelligence and bioengineering to accelerate therapeutic innovation and design next-generation immunotherapies. Learn how we’re shaping the future of precision medicine.
Funding History
1Total raised: $2.5M
Seed$2.5MUndisclosedMar 15, 2022
Company Info
TypePrivate
Founded2018
LocationOxford, United Kingdom
StageApproved
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile